Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 11;13(20):6049.
doi: 10.3390/jcm13206049.

No Effect of Low-Dose Glucocorticoid Maintenance Therapy on Damage in SLE Patients in Prolonged Remission: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort

Guillermo Ruiz-Irastorza  1   2 , Diana Paredes-Ruiz  1 , Luis Dueña-Bartolome  1 , Halbert Hernandez-Negrin  1   3   4 , Victor Moreno-Torres  1   5   6 , Christophe Richez  7 , Estibaliz Lazaro  7
Affiliations

No Effect of Low-Dose Glucocorticoid Maintenance Therapy on Damage in SLE Patients in Prolonged Remission: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort

Guillermo Ruiz-Irastorza et al. J Clin Med. .

Abstract

Background/Objectives: Prolonged remission on low-dose glucocorticoids (GC) is a main goal in patients with systemic lupus erythematosus (SLE). The aim of this study is to assess whether GC ≤ 5 mg/d increases the risk of damage accrual in patients with SLE in prolonged remission. Methods: Observational study of routine clinical care data of the inception Lupus Cruces-Bordeaux cohort. Only patients in DORIS remission during five consecutive yearly visits were included. The endpoint was damage accrual during the 5-year follow-up, either global or specific damage: GC-induced, cardiovascular (CV), lupus and other. Patients no longer on GC therapy by year 5 (GC5-Off) were compared with those who continued GC therapy (GC5-On). Comparisons were made by Cox and Poisson regressions, which were adjusted with propensity score (PE) in order to control for confounding by indication. Results: 132 patients were included, 56 in the GC5-On and 76 in the GC5-Off groups. All patients were on GC ≤ 5 mg/d for the whole follow-up, the mean prednisone dose in the GC5-On group being 2.96 mg/d during the whole study period and 2.6 mg/d during the 5th year. Fourteen patients (10.6%) accrued damage. More patients in the GC5-On group accrued global damage, 16% vs. 7% in the GC5-Off group, p = 0.08, mainly at CV domains (7% vs. 1%, respectively, p = 0.16). In the PS-adjusted Cox and Poisson regressions, the GC5-On group was not significantly associated with global (p = 0.39) or CV damage accrual (p = 0.62), nor with the absolute (p = 0.40) or CV-restricted final SDI scores (p = 0.63). The C-index of the propensity score model was 0.79. Conclusions: Maintaining doses of prednisone < 5 mg/d in lupus patients in prolonged remission is not associated with an increased risk of damage accrual.

Keywords: damage; glucocorticoids; hydroxychloroquine; remission; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Gladman D., Ginzler E., Goldsmith C., Fortin P.R., Liang M., Urowitz M.B., Bacon P., Bombardieri S., Hanly J., Hay E., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–369. doi: 10.1002/art.1780390303. - DOI - PubMed
    1. Bruce I.N., O’Keeffe A.G., Farewell V., Hanly J.G., Manzi S., Su L., Gladman D.D., Bae S.-C., Sánchez-Guerrero J., Romero-Díaz J., et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 2015;74:1706–1713. doi: 10.1136/annrheumdis-2013-205171. - DOI - PMC - PubMed
    1. van Vollenhoven R.V., Voskuyl A., Bertsias G., Aranow C., Aringer M., Arnaud L., Askanase A., Balážová P., Bonfa E., Bootsma H., et al. A Framework for Remission in SLE: Consensus Findings from a Large International Task Force on Definitions of Remission in SLE (DORIS) Ann. Rheum. Dis. 2016;76:554–561. doi: 10.1136/annrheumdis-2016-209519. - DOI - PubMed
    1. Ruiz-Irastorza G., Ruiz-Estevez B., Lazaro E., Ruiz-Arruza I., Duffau P., Martin-Cascón M., Richez C., Ugarte A., Blanco P. Prolonged Remission in SLE Is Possible by Using Reduced Doses of Prednisone: An Observational Study from the Lupus-Cruces and Lupus-Bordeaux Inception Cohorts. Autoimmun. Rev. 2019;18:102359. doi: 10.1016/j.autrev.2019.102359. - DOI - PubMed
    1. Ugarte-Gil M.F., Hanly J., Urowitz M., Gordon C., Bae S.-C., Romero-Diaz J., Sanchez-Guerrero J., Bernatsky S., Clarke A.E., Wallace D.J., et al. Remission and Low Disease Activity (LDA) Prevent Damage Accrual in Patients with Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 2022;81:1541–1548. doi: 10.1136/ard-2022-222487. - DOI - PMC - PubMed

LinkOut - more resources